Agno Pharma
James Chen is an experienced leader in the pharmaceutical industry, currently serving as CEO of Agno Pharma since 2003. Prior to this role, James held positions as Principal Scientist and CMC Leader at Schering-Plough (now Merck) from 2000 to 2003, and as Principal Investigator at DuPont Merck (now BMS) from 1995 to 2000. James holds a Ph.D. in Chemistry from the University of Pittsburgh, obtained in 1995, and a B.Sc. in Chemistry from Stony Brook University, earned in 1990.
This person is not in any teams
This person is not in any offices
Agno Pharma
Agno Pharmaceuticals is a global CDMO supplying critical RSMs, intermediates, active pharmaceutical ingredients (APIs), highly potent APIs, sterile APIs, and sterile drug product formulations to large and medium-sized pharmaceutical, biotech, generic and CDMO customers. Founded in 2004, Agno has process development and US-FDA inspected GMP-compliant manufacturing facilities with sterile suspension injectable manufacturing capabilities. In addition, Agno has established a drug product formulation research and development laboratory for complex injectables. Agno Pharmaceuticals has invested in its people and facilities and established a broad spectrum of service capabilities throughout the entire drug development and commercialization process. Agno Pharmaceuticals has an excellent track record in the delivery of both development and commercial stage cGMP manufacturing solutions to its customers in North America and Europe.